Boston, MA 05/13/2014 (wallstreetpr) – A leading player in the biopharmaceutical companies, Gilead Sciences, Inc. (NASDAQ:GILD) is making an aggressive move towards giving a series of positive innovational results. Owing to the growing demands of the industry and consumers, Gilead Sciences have developed a number of drugs and therapies to eradicate the critical syndrome and diseases. It has recently announced the result of the Phase study of the new revolutionary therapy and drugs that are capable of fighting Atrial Fibrillation and Long QT-3 syndrome. Further, the earlier launch Sovaldi drug has also marked a huge success in the industry and is still growing.
Announcement of Phase-2 study from HARMONY
Gilead Sciences, Inc. (NASDAQ:GILD) have recently announced the result from HARMONY; a Phase 2 study of single and in combination of low-dose dronedarone and ranolazine to analyze its effect on atrial fibrillation burden (AFB) with paroxysmal atrial fibrillation. The Phase two results revealed a greater reduction effect in AFB.
Peter R. Kowey remarked that HARMONY s playing a crucial role in lowering the AP burden in patients as compared to any other drug. Harmony is a breakthrough development in the medical industry due to a limited number of therapies for the atrial fibrillation. It has provided a safeguard for addressing minimal treatment options.
Treatment scope of QT-3 Syndrome
Gilead Sciences, Inc. (NASDAQ:GILD) has recently revealed the Phase one trial result of GS-6615 in patients that are suffering from a genetic disorder i.e. with Long QT-3 Syndrome. It acts to curtail or combat the genetic disorder leading to abnormal heartbeats thereby reducing the QTc interval. Professor of Cardiology, Arthur J Moss, remarked that there have been limited discoveries in the LQTS domain. Thus, the latest discovery by Gilead Sciences has enabled the emergence of novel breakthrough for the fatal disease. The inhibition character of GS-6615 has been proved thereby enhancing the crucial role in the treatment of heart diseases in the patients.
